430 related articles for article (PubMed ID: 16601995)
1. Effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia.
Wu RR; Zhao JP; Liu ZN; Zhai JG; Guo XF; Guo WB; Tang JS
Psychopharmacology (Berl); 2006 Jul; 186(4):572-8. PubMed ID: 16601995
[TBL] [Abstract][Full Text] [Related]
2. Sex difference in effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia.
Wu RR; Zhao JP; Zhai JG; Guo XF; Guo WB
J Clin Psychopharmacol; 2007 Aug; 27(4):374-9. PubMed ID: 17632222
[TBL] [Abstract][Full Text] [Related]
3. Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis.
Henderson DC; Cagliero E; Copeland PM; Borba CP; Evins AE; Hayden D; Weber MT; Anderson EJ; Allison DB; Daley TB; Schoenfeld D; Goff DC
Arch Gen Psychiatry; 2005 Jan; 62(1):19-28. PubMed ID: 15630069
[TBL] [Abstract][Full Text] [Related]
4. Effects of second-generation antipsychotics on selected markers of one-carbon metabolism and metabolic syndrome components in first-episode schizophrenia patients.
Misiak B; Frydecka D; Łaczmański Ł; Ślęzak R; Kiejna A
Eur J Clin Pharmacol; 2014 Dec; 70(12):1433-41. PubMed ID: 25291992
[TBL] [Abstract][Full Text] [Related]
5. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics.
Lindenmayer JP; Czobor P; Volavka J; Citrome L; Sheitman B; McEvoy JP; Cooper TB; Chakos M; Lieberman JA
Am J Psychiatry; 2003 Feb; 160(2):290-6. PubMed ID: 12562575
[TBL] [Abstract][Full Text] [Related]
6. Effects of olanzapine and risperidone on glucose metabolism and insulin sensitivity in chronic schizophrenic patients with long-term antipsychotic treatment: a randomized 5-month study.
Smith RC; Lindenmayer JP; Davis JM; Kelly E; Viviano TF; Cornwell J; Hu Q; Khan A; Vaidhyanathaswamy S
J Clin Psychiatry; 2009 Nov; 70(11):1501-13. PubMed ID: 19814947
[TBL] [Abstract][Full Text] [Related]
7. Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics.
Atmaca M; Kuloglu M; Tezcan E; Ustundag B
J Clin Psychiatry; 2003 May; 64(5):598-604. PubMed ID: 12755665
[TBL] [Abstract][Full Text] [Related]
8. Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis.
Rummel-Kluge C; Komossa K; Schwarz S; Hunger H; Schmid F; Lobos CA; Kissling W; Davis JM; Leucht S
Schizophr Res; 2010 Nov; 123(2-3):225-33. PubMed ID: 20692814
[TBL] [Abstract][Full Text] [Related]
9. A randomized, 12-week study of the effects of extended-release paliperidone (paliperidone ER) and olanzapine on metabolic profile, weight, insulin resistance, and β-cell function in schizophrenic patients.
Hu S; Yao M; Peterson BS; Xu D; Hu J; Tang J; Fan B; Liao Z; Yuan T; Li Y; Yue W; Wei N; Zhou W; Huang M; Xu Y
Psychopharmacology (Berl); 2013 Nov; 230(1):3-13. PubMed ID: 23559220
[TBL] [Abstract][Full Text] [Related]
10. Effects of olanzapine and risperidone on lipid metabolism in chronic schizophrenic patients with long-term antipsychotic treatment: a randomized five month study.
Smith RC; Lindenmayer JP; Hu Q; Kelly E; Viviano TF; Cornwell J; Vaidhyanathaswamy S; Marcovina S; Davis JM
Schizophr Res; 2010 Jul; 120(1-3):204-9. PubMed ID: 20457512
[TBL] [Abstract][Full Text] [Related]
11. Effect of antipsychotic-induced hyperprolactinemia on anthropometric measures, insulin sensitivity and lipid profile in patients with schizophrenia or related psychoses.
Melkersson K; Berinder K; Hulting AL
Neuro Endocrinol Lett; 2011; 32(4):428-36. PubMed ID: 21876517
[TBL] [Abstract][Full Text] [Related]
12. Glucose and lipid disturbances after 1 year of antipsychotic treatment in a drug-naïve population.
Perez-Iglesias R; Mata I; Pelayo-Teran JM; Amado JA; Garcia-Unzueta MT; Berja A; Martinez-Garcia O; Vazquez-Barquero JL; Crespo-Facorro B
Schizophr Res; 2009 Feb; 107(2-3):115-21. PubMed ID: 18993033
[TBL] [Abstract][Full Text] [Related]
13. The effects of novel antipsychotics on glucose and lipid levels.
Wirshing DA; Boyd JA; Meng LR; Ballon JS; Marder SR; Wirshing WC
J Clin Psychiatry; 2002 Oct; 63(10):856-65. PubMed ID: 12416594
[TBL] [Abstract][Full Text] [Related]
14. [Effects of ziprasidone and olanzapine on glucose and lipid metabolism in first-episode schizophrenia].
Shao P; Ou J; Wu R; Fang M; Chen H; Xu Y; Zhao J
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2013 Apr; 38(4):365-9. PubMed ID: 23645236
[TBL] [Abstract][Full Text] [Related]
15. Glucose metabolism in Japanese schizophrenia patients treated with risperidone or olanzapine.
Yasui-Furukori N; Sato Y; Furukori H; Saito M; Nakagami T; Kaneko S
J Clin Psychiatry; 2009 Jan; 70(1):95-100. PubMed ID: 19026267
[TBL] [Abstract][Full Text] [Related]
16. Allelic variation in ApoC3, ApoA5 and LPL genes and first and second generation antipsychotic effects on serum lipids in patients with schizophrenia.
Smith RC; Segman RH; Golcer-Dubner T; Pavlov V; Lerer B
Pharmacogenomics J; 2008 Jun; 8(3):228-36. PubMed ID: 17726453
[TBL] [Abstract][Full Text] [Related]
17. [Therapy with antipsychotic drugs as a risk factor for diabetes in schizophrenia: a case-control study].
Rubio G; Gómez-de-la-Cámara A; Ledesma F; Burón JA; Rodríguez-Morales A; Martínez-Junquera G;
Med Clin (Barc); 2006 Apr; 126(12):441-4. PubMed ID: 16620729
[TBL] [Abstract][Full Text] [Related]
18. A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcomes after 1 year.
Meyer JM
J Clin Psychiatry; 2002 May; 63(5):425-33. PubMed ID: 12019668
[TBL] [Abstract][Full Text] [Related]
19. Relationship between levels of insulin or triglycerides and serum concentrations of the atypical antipsychotics clozapine and olanzapine in patients on treatment with therapeutic doses.
Melkersson KI; Dahl ML
Psychopharmacology (Berl); 2003 Nov; 170(2):157-66. PubMed ID: 12851739
[TBL] [Abstract][Full Text] [Related]
20. Metabolic risk with second-generation antipsychotic treatment: a double-blind randomized 8-week trial of risperidone and olanzapine.
Kelly DL; Conley RR; Love RC; Morrison JA; McMahon RP
Ann Clin Psychiatry; 2008; 20(2):71-8. PubMed ID: 18568578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
